ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $944,219 | -5.1% | 45,308 | +9.1% | 0.00% | 0.0% |
| Q2 2023 | $994,811 | +107.7% | 41,537 | +63.2% | 0.00% | +100.0% |
| Q1 2023 | $478,856 | +12.7% | 25,444 | +54.6% | 0.00% | 0.0% |
| Q1 2021 | $425,000 | -80.6% | 16,458 | -59.9% | 0.00% | -77.8% |
| Q4 2020 | $2,194,000 | +15.5% | 41,038 | -10.9% | 0.01% | 0.0% |
| Q3 2020 | $1,900,000 | -49.5% | 46,063 | -40.7% | 0.01% | -50.0% |
| Q2 2020 | $3,766,000 | +36.4% | 77,704 | +18.9% | 0.02% | +5.9% |
| Q1 2020 | $2,760,000 | +43.2% | 65,330 | +45.1% | 0.02% | +70.0% |
| Q4 2019 | $1,927,000 | +29.2% | 45,033 | +8.6% | 0.01% | +25.0% |
| Q3 2019 | $1,492,000 | +255.2% | 41,459 | +163.7% | 0.01% | +300.0% |
| Q2 2019 | $420,000 | -52.6% | 15,720 | -52.4% | 0.00% | -60.0% |
| Q1 2019 | $887,000 | -87.1% | 33,045 | -92.7% | 0.01% | -86.8% |
| Q2 2018 | $6,877,000 | +1553.1% | 450,345 | +3425.2% | 0.04% | +850.0% |
| Q1 2015 | $416,000 | – | 12,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |